Can Adalimumab (Humira) Be Used Once Weekly Instead of Biweekly?
Yes, adalimumab can be used once weekly instead of biweekly, but this is specifically indicated for patients who have inadequate response to the standard every-other-week dosing, not as a first-line regimen.
Standard Dosing Remains Biweekly
The FDA-approved and guideline-recommended maintenance dose for adalimumab across most indications is 40 mg every 2 weeks 1, 2. This applies to:
- Rheumatoid arthritis
- Psoriatic arthritis
- Plaque psoriasis
- Crohn's disease
- Ulcerative colitis
- Hidradenitis suppurativa
When Weekly Dosing Is Appropriate
Psoriasis
For patients with inadequate response after 16 weeks of biweekly dosing, escalation to 40 mg weekly is recommended 1. The AAD-NPF guidelines give this a Grade A recommendation, indicating strong evidence supporting weekly dosing as a rescue strategy for partial responders 1.
A 2018 study demonstrated that 27.8% of psoriasis patients required dose escalation to weekly dosing during long-term treatment, with 52.1% of those escalated patients achieving sufficient improvement to warrant continuation 3. This validates weekly dosing as an effective salvage option.
Ulcerative Colitis
Weekly dosing has proven particularly valuable in ulcerative colitis. Research shows that 16.3% of week-8 responders and 38.4% of week-8 non-responders required escalation to weekly dosing 4. Among those escalated:
- Week-8 responders achieved 45% remission and 45% mucosal healing at week 52
- Week-8 non-responders achieved 25% response and 29.2% mucosal healing 4
The FDA label confirms that some UC patients receive 40 mg weekly with mean steady-state trough concentrations of approximately 15 mcg/mL, compared to 8 mcg/mL with biweekly dosing 2.
Crohn's Disease
For Crohn's disease patients losing response to biweekly dosing, escalation to 40 mg weekly is recommended before considering treatment failure 5. Evidence even supports escalation to 80 mg weekly in refractory cases, with 33.3% achieving clinical remission and 54.8% showing clinical response 6.
Hidradenitis Suppurativa
The FDA-approved regimen for HS is already 40 mg weekly as the standard maintenance dose 2. Some patients with suboptimal response may benefit from further escalation to 80 mg weekly, though evidence is limited 7.
Clinical Algorithm for Dose Escalation
- Start all patients (except HS) on 40 mg every 2 weeks after appropriate loading doses
- Assess response at 8-16 weeks depending on indication
- If inadequate response (not meeting disease-specific targets like PASI 50 for psoriasis or clinical remission for IBD):
- Rule out non-inflammatory causes of symptoms (infection, bile acid diarrhea, IBS)
- Check adalimumab trough levels if available
- Escalate to 40 mg weekly
- Reassess at 6-12 weeks after escalation
- If response achieved on weekly dosing, continue; some patients may later de-escalate back to biweekly if sustained remission achieved 3
Important Caveats
- Prior anti-TNF use predicts need for dose escalation 4, so these patients may require closer monitoring
- Weekly dosing shows no new safety signals compared to biweekly dosing across multiple studies 4, 3, 6
- Higher body weight correlates with lower adalimumab concentrations 7, potentially necessitating dose intensification
- Pediatric dosing differs: For pediatric Crohn's disease, weekly dosing is NOT the recommended maintenance regimen 2
Biosimilars
The same dosing principles apply to adalimumab biosimilars, which demonstrate equivalent effectiveness to Humira at both biweekly and weekly dosing frequencies 8, 9. Product attributes (citrate-free formulation, needle gauge, injection volume) may influence patient experience but not clinical efficacy 10.
Bottom line: Weekly adalimumab dosing is evidence-based and guideline-supported, but should be reserved for patients with documented inadequate response to standard biweekly dosing, not used as initial therapy.